The approvals from the Florida and Alabama Medicaid health programs for the poor and disabled mark exceptionally fast acceptance for the treatment, which can cost up to $113,000 annually for an individual patient, excluding discounts, said Ameet Mallik, who heads the Swiss drugmaker’s oncology division. In November, the U.S. Food and Drug Administration approved Adakveo and Global Blood Therapeutic Inc’s Oxbryta, which carries a list price of $125,000 per year. …read more
Source:: Yahoo Finance
